Laddar...
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
BACKGROUND: This multicentre, open‐label study evaluated the efficacy and safety of antiprogrammed death ligand 1 antibody SHR‐1316 plus liposomal irinotecan and 5‐fluorouracil as the first‐line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS: Eligible patient...
Sparad:
| I publikationen: | Thorac Cancer |
|---|---|
| Huvudupphovsmän: | , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
John Wiley & Sons Australia, Ltd
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8088918/ https://ncbi.nlm.nih.gov/pubmed/33760397 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13913 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|